Generation Bio
GBIO
GBIO was delisted on the 6th of February, 2026.
74 hedge funds and large institutions have $224M invested in Generation Bio in 2024 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 26 increasing their positions, 27 reducing their positions, and 12 closing their positions.
153% more capital invested
Capital invested by funds: $88.5M → $224M (+$135M)
0.15% more ownership
Funds ownership: 8.12% → 8.27% (+0.15%)
0% more funds holding
Funds holding: 74 → 74 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 12
4% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.6M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$1.09M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$874K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$602K |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$576K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2.79M |
| 2 |
Millennium Management
New York
|
-$1.25M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$421K |
| 4 |
BlackRock
New York
|
-$282K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$204K |
GBIO Hedge Fund Activity: Q1 2024 in Review
74 of the 6,946 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q1 2024, worth a combined $224M — up 153% from $88.5M a quarter earlier.
Fund positioning in GBIO was balanced in Q1 2024: 12 funds opened new positions, 12 closed out, 26 added to existing stakes and 27 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $4.6M. The largest seller was Morgan Stanley, cutting an estimated $2.79M.
- 74 institutional investors held Generation Bio (GBIO) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $224M of Generation Bio stock for Q1 2024, up 153% quarter-over-quarter.
- 12 funds opened new Generation Bio positions in Q1 2024 and 12 closed out, a net change of 0 holders.
- The largest Generation Bio buyer in Q1 2024 was T. Rowe Price Associates, an estimated $4.6M added.
- The largest Generation Bio seller in Q1 2024 was Morgan Stanley, an estimated $2.79M sold.
Based on aggregated 13F filings for Q1 2024.